FTC Can Seek Disgorgement In Cephalon Suit, Judge Says

Law360, New York (April 16, 2015, 1:48 PM EDT) -- The Federal Trade Commission can pursue billions of dollars Cephalon Inc. allegedly made through a series of pay-for-delay deals meant to stave off competition with its blockbuster narcolepsy drug, a Pennsylvania federal judge ruled Wednesday.

U.S. District Judge Mitchell Goldberg rejected a number of arguments from Cephalon, allowing the FTC to seek disgorgement of profits the company allegedly secured between 2007 and 2012 by using a fraudulent patent to pay generic-drug makers to delay launching their own versions of Provigil.

The watchdog agency's expert has estimated...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

FEDERAL TRADE COMMISSION v. CEPHALON, INC.


Case Number

2:08-cv-02141

Court

Pennsylvania Eastern

Nature of Suit

Other Statutes: Anti-Trust

Judge

MITCHELL S. GOLDBERG

Date Filed

May 8, 2008

Law Firms

Companies

Government Agencies

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.